Fast and Sensitive HPLC-ESI-MS/MS Method for Etoricoxib Quantification in Human Plasma and Application to Bioequivalence Study

Molecules. 2022 Sep 4;27(17):5706. doi: 10.3390/molecules27175706.

Abstract

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. The objective of the current study was to develop a sensitive, fast and high-throughput HPLC-ESI-MS/MS method to measure etoricoxib levels in human plasma using a one-step methanol protein precipitation technique. A tandem mass spectrometer equipped with an electrospray ionization (ESI) source operated in a positive mode and multiple reaction monitoring (MRM) were used for data collection. The quantitative MRM transition ions were m/z 359.15 > 279.10 and m/z 363.10 > 282.10 for etoricoxib and IS. The linear range was from 10.00 to 4000.39 ng/mL and the validation parameters were within the acceptance limits of the European Medicine Agency (EMA) and Food and Drug Analysis (FDA) guidelines. The present method was sensitive (10.00 ng/mL with S/N > 40), simple, selective (K prime > 2), and fast (short run time of 2 min), with negligible matrix effect and consistent recovery, suitable for high throughput analysis. The method was used to quantitate etoricoxib plasma concentrations in a bioequivalence study of two 120 mg etoricoxib formulations. Incurred sample reanalysis results further supported that the method was robust and reproducible.

Keywords: bioequivalence study; etoricoxib; etoricoxib D4; high-sample throughput; human plasma; protein precipitation.

MeSH terms

  • Chromatography, High Pressure Liquid / methods
  • Etoricoxib
  • Humans
  • Reproducibility of Results
  • Spectrometry, Mass, Electrospray Ionization* / methods
  • Tandem Mass Spectrometry* / methods
  • Therapeutic Equivalency

Substances

  • Etoricoxib

Grants and funding

The study was funded by Y.S.P. Industries (M) Sdn. Bhd.